Suven Pharmaceuticals announced that its Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India, have completed the Pre Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by the US Food & Drug Administration (US FDA) today. The inspection was conducted from 12 February 2024, to 23 February 2024, and no Form 483 has been issued as a result of the inspection
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
